8-K: Biote Corp. Appoints Robert Peterson as New Chief Financial Officer

Biote Corp. has appointed Robert Peterson as its new Chief Financial Officer, effective January 8, 2024, succeeding Samar Kamdar who will remain with the company through February 29, 2024 to assist with the transition.

Summary

• Biote Corp. has appointed Robert Peterson as its new Chief Financial Officer, effective January 8, 2024.
• Robert Peterson succeeds Samar Kamdar, who will stay with the company until February 29, 2024, to aid in the transition.
• Mr. Peterson joins Biote from Virbac Corp., where he served as CFO from September 2017 to January 2024.
• Mr. Peterson's compensation includes an annual base salary of $425,000, a potential annual bonus of up to 50% of his base salary, restricted stock units valued at $177,000, and 400,000 stock options.
• Samar Kamdar's departure is not related to the company's financial results or any disagreements over accounting practices.
• Mr. Kamdar will receive his current base salary and is eligible for up to $140,000 in additional severance benefits during his transition period.

Sentiment

Score: 7

Explanation: The document conveys a positive sentiment due to the appointment of a new CFO with relevant experience and a smooth transition plan. However, the departure of the previous CFO and the inherent risks in the business temper the overall sentiment.

Positives

• The appointment of Robert Peterson brings 15 years of health and wellness industry experience and public company experience to Biote.
• Mr. Peterson's background includes leadership roles at Virbac Corp. and Alcon Laboratories/Novartis Eye Care.
• The transition plan ensures continuity with Samar Kamdar staying on to assist with the handover.
• The company has provided a clear explanation that the CFO transition is not related to financial performance or accounting issues.

Negatives

• The departure of a key executive, even with a transition plan, can create uncertainty.
• The company is incurring additional costs related to the transition, including potential severance payments to the outgoing CFO.

Risks

• The company faces risks related to the market acceptance of its dietary supplements.
• There is reliance on third parties for the manufacturing of bio-identical hormones.
• The company is sensitive to regulatory, economic, environmental, and competitive conditions.
• There are risks associated with the company's ability to grow its business and expand into new markets.
• The company faces significant competition in its industry.
• The company has a limited operating history.
• There are risks related to protecting intellectual property and heavy regulatory oversight.
• The company may be impacted by economic, business, and competitive factors, including bank failures and exchange and interest rates.

Future Outlook

The company aims to maximize growth opportunities, improve operating efficiencies, and achieve its financial objectives under the leadership of the new CFO. The company is focused on expanding in the growing market for therapeutic wellness.

Management Comments

• Terry Weber, Biote Chief Executive Officer, stated that Robert Peterson is a proven and highly accomplished finance executive.
• Ms. Weber also thanked Samar Kamdar for his valuable contributions.
• Robert Peterson expressed his pleasure in joining Biote at this pivotal time and looks forward to working with the management team.

Industry Context

The appointment of a new CFO is a common event in the corporate world, but it is particularly relevant for a company like Biote, which is operating in the growing market of therapeutic wellness. The company's focus on personalized hormone optimization and therapeutic wellness solutions aligns with the broader trend of preventive healthcare.

Comparison to Industry Standards

• The appointment of a new CFO with experience in the health and wellness industry is a common practice for companies in this sector.
• The compensation package for the new CFO, including base salary, bonus potential, stock options, and restricted stock units, is generally in line with industry standards for similar roles.
• The transition plan for the outgoing CFO, including a transition period and potential severance benefits, is also a standard practice to ensure a smooth handover of responsibilities.
• Virbac S.A., where Mr. Peterson previously served as CFO, is a global veterinary pharmaceutical and wellness company, which is a comparable company in the health and wellness sector.
• Alcon Laboratories/Novartis Eye Care, where Mr. Peterson also held roles, is another comparable company in the healthcare industry.

Management Changes

Stakeholder Impact

• Shareholders may react to the change in leadership, but the company has emphasized that the transition is not due to financial or accounting issues.
• Employees may experience some changes due to the new CFO's leadership style and priorities.
• Customers and suppliers are unlikely to be directly impacted by this management change.

Next Steps

• Robert Peterson will assume his role as Chief Financial Officer, effective January 8, 2024.
• Samar Kamdar will remain with the company through February 29, 2024, to assist with the transition.
• The full text of the Employment Agreement and Transition Agreement will be filed as exhibits to the company's Annual Report on Form 10-K for the year ended December 31, 2023.

Key Dates

Keywords

Chief Financial Officer, CFO, executive transition, management change, financial officer, Robert Peterson, Samar Kamdar, biote corp, BTMD, hormone optimization, therapeutic wellness